Compare Quanta Services Inc (PWR) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quanta Services Inc vs Tango Therapeutics Inc. — how do they compare? Quanta Services Inc trades at $650.02 (market cap $103.57B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Quanta Services Inc is far larger — about 27.6× Tango Therapeutics Inc.'s market cap, and Quanta Services Inc pays a 0.06% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quanta Services Inc for 62 Days and Tango Therapeutics Inc. for 0 Days on average.
| PWR | TNGX | |
|---|---|---|
Market Cap | $103.57B | $3.75B |
Volume | 1,036,513 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $785.24 | $32.90 |
52-Week Low | $412.21 | $7.50 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $109.67B | $2.77B |
Dividend Yield | 0.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PWR trades at $660.53, down 4.93% for the day, but maintains strong analyst support with 27 buy ratings and a $802.08 consensus price target. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.24 surpassing expectations by 28%. Technical indicators show a bullish trend with support at $682 and resistance at $706. Revenue growth remains robust, climbing from $17.1B in 2022 to $28.5B in 2025.
PWR presents a compelling growth story with strong earnings momentum and a record $53B backlog supporting future revenue. However, elevated valuation ratios (P/E 78.82, EV/EBITDA 35.6) and negative cash flow trends pose risks. The stock offers 21% upside to consensus targets, but investors should weigh premium valuation against execution risks in large infrastructure projects.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
